FCG Investment Co Has $1.78 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

FCG Investment Co increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 10.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,040 shares of the biotechnology company’s stock after purchasing an additional 472 shares during the period. United Therapeutics makes up approximately 1.1% of FCG Investment Co’s investment portfolio, making the stock its 26th largest holding. FCG Investment Co’s holdings in United Therapeutics were worth $1,778,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in UTHR. JPMorgan Chase & Co. grew its position in shares of United Therapeutics by 35.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after buying an additional 50,291 shares during the period. Franklin Resources Inc. grew its holdings in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after purchasing an additional 123,929 shares during the period. Burney Co. increased its stake in United Therapeutics by 113.3% in the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after purchasing an additional 12,705 shares in the last quarter. Bridgewater Associates LP raised its holdings in United Therapeutics by 384.3% in the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock worth $22,130,000 after purchasing an additional 49,003 shares during the period. Finally, Glenmede Trust Co. NA raised its holdings in United Therapeutics by 6.4% in the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after purchasing an additional 4,145 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 224 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $412.28, for a total value of $92,350.72. Following the completion of the sale, the director now owns 5,783 shares in the company, valued at approximately $2,384,215.24. This trade represents a 3.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,848 shares of company stock worth $55,165,099 in the last ninety days. Insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on UTHR shares. LADENBURG THALM/SH SH upped their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Price Performance

United Therapeutics stock opened at $371.89 on Friday. The firm has a 50-day moving average of $365.04 and a 200-day moving average of $355.24. The company has a market cap of $16.60 billion, a price-to-earnings ratio of 16.33, a P/E/G ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% compared to the same quarter last year. During the same period last year, the company earned $5.38 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.